Addressing Treatment Gaps in HER2+ MBC
Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Optimizing Therapy in HER2+ MBC Across the Globe
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
Therapeutic Sequencing in HER2+ MBC
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
ADCs Under Investigation for HER2+ MBC
Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.
Updates in the Management of HER2+ MBC With Brain Metastases
Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.
Therapeutic Advances in Prophylaxis Against CIN
An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
CIN: Adopting SIMBA Therapy Into Clinical Practice
A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.
CIN: Implications of the PROTECTIVE-2 Study
Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.
Subgroup Analyses of DESTINY-Breast03 in HER2+ MBC
Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.
CIN: Takeaways From the PROTECTIVE-1 Study
An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.
Potential Dosing Strategies to Mitigate CIN
Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.
CIN Prophylaxis and Bone Pain
Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.
Standard Treatment Approaches in HER2+ MBC
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
Global Trends in HER2+ MBC
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
Anticancer Therapy: Safety vs Efficacy
Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.
Managing CIN in Patients With Breast Cancer
Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.
CIN Prophylaxis: Treating With G-CSFs
Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.
G-CSFs for Chemotherapy-Induced Neutropenia
Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.
Guideline Recommendations for CIN Prophylaxis
Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.
Notable ASCO Trial Updates
HER2+ MBC Adverse-Event Management
After Progression on PIK3CAi Therapy: MTOR Inhibition
Significance of PIK3CA Mutation in HR+ Breast Cancer
Mechanisms of Resistance to CDK4/6 Inhibitors
CDK4/6 Meta-Analysis Data
CDK4/6 Clinical Trial Survival Data Impact
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer
Next-Generation Sequencing: Triple Negative Breast Cancer
Phase 3 ASCENT Regimen Accelerated Approval
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512